Beebe-Dimmer J L, Lange L A, Cain J E, Lewis R C, Ray A M, Sarma A V, Lange E M, Cooney K A
Department of Urology, University of Michigan Medical School, Ann Arbor MI, USA.
Prostate Cancer Prostatic Dis. 2006;9(1):50-5. doi: 10.1038/sj.pcan.4500840.
A major problem with the use of serum prostate-specific antigen (PSA) in predicting prostate cancer risk is the considerable variability of such measurements. Cramer et al. identified a set of single-nucleotide polymorphisms (SNPs) in the upstream regulatory region of the PSA gene that were each associated with increased promoter activity and serum PSA, further suggesting that genotyping these SNPs could be useful in improving the predictive value of PSA screening. In order to replicate this finding, DNA samples from 475 African-American men were genotyped for the same SNPs and no association was observed with either serum PSA level or prostate cancer diagnosis.
使用血清前列腺特异性抗原（PSA）来预测前列腺癌风险的一个主要问题是此类测量结果存在相当大的变异性。克莱默等人在PSA基因的上游调控区域鉴定出一组单核苷酸多态性（SNP），每个SNP都与启动子活性增强和血清PSA相关，这进一步表明对这些SNP进行基因分型可能有助于提高PSA筛查的预测价值。为了重复这一发现，对475名非裔美国男性的DNA样本进行了相同SNP的基因分型，未观察到与血清PSA水平或前列腺癌诊断之间存在关联。
